Beren Therapeutics, P.B.C. announced that its novel lead asset, BRN-002, was awarded an Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway, for the reversal of atherosclerosis in patients with Homozygous Familial Hypercholesterolemia.
November 17, 2022
· 3 min read
